<div class="infobox infobox-protein">
<div class="infobox-header">Disintegrin and Metalloproteinase Domain 15</div>
<div class="infobox-row"><span class="infobox-label">Gene</span><span class="infobox-value">[ADAM15](/genes/adam15)</span></div>
<div class="infobox-row"><span class="infobox-label">UniProt</span><span class="infobox-value">[Q13487](https://www.uniprot.org/uniprot/Q13487)</span></div>
<div class="infobox-row"><span class="infobox-label">PDB Structures</span><span class="infobox-value">4TXH, 4TY4</span></div>
<div class="infobox-row"><span class="infobox-label">Molecular Weight</span><span class="infobox-value">87.8 kDa</span></div>
<div class="infobox-row"><span class="infobox-label">Subcellular Localization</span><span class="infobox-value">Plasma membrane, Cell surface, Intracellular vesicles</span></div>
<div class="infobox-row"><span class="infobox-label">Protein Family</span><span class="infobox-value">ADAM (A Disintegrin and Metalloproteinase) family</span></div>
</div>
<div class="infobox infobox-protein">
<div class="infobox-header">Disintegrin and Metalloproteinase Domain 15</div>
<div class="infobox-row"><span class="infobox-label">Gene</span><span class="infobox-value">[ADAM15](/genes/adam15)</span></div>
<div class="infobox-row"><span class="infobox-label">UniProt</span><span class="infobox-value">[Q13487](https://www.uniprot.org/uniprot/Q13487)</span></div>
<div class="infobox-row"><span class="infobox-label">PDB Structures</span><span class="infobox-value">4TXH, 4TY4</span></div>
<div class="infobox-row"><span class="infobox-label">Molecular Weight</span><span class="infobox-value">87.8 kDa</span></div>
<div class="infobox-row"><span class="infobox-label">Subcellular Localization</span><span class="infobox-value">Plasma membrane, Cell surface, Intracellular vesicles</span></div>
<div class="infobox-row"><span class="infobox-label">Protein Family</span><span class="infobox-value">ADAM (A Disintegrin and Metalloproteinase) family</span></div>
</div>
ADAM15 (A Disintegrin and Metalloproteinase 15) is a member of the ADAM family of membrane-anchored metalloproteinases that play critical roles in cell adhesion, proteolysis, and signaling. ADAM15 stands out as the only ADAM family member that possesses both an active metalloproteinase domain and an arginine-glutamic acid (RGD) sequence in its disintegrin domain, a unique combination that enables potent integrin binding and proteolytic activity simultaneously[@hure2019]. This dual functionality makes ADAM15 a key regulator of cell-cell and cell-matrix interactions in both physiological and pathological contexts.
The protein is widely expressed across multiple tissue types, including the brain, where it participates in various neurodegenerative processes. ADAM15 has emerged as a significant player in Alzheimer's disease (AD), Parkinson's disease (PD), stroke, and other neurovascular disorders. Its expression pattern and functional properties make it a molecule of interest for understanding the molecular mechanisms underlying neurodegeneration and for developing potential therapeutic interventions.
ADAM15 possesses a complex multi-domain architecture that underlies its diverse functional capabilities. Each domain contributes to specific aspects of ADAM15's activity in normal physiology and disease states.
The N-terminal metalloproteinase domain contains the zinc-dependent catalytic center essential for proteolytic activity. This domain is responsible for the shedding of membrane-bound proteins, including growth factors, cytokines, and adhesion molecules. The catalytic activity of ADAM15 is conferred by the conserved HEXGHNLG motif characteristic of the metzincin family of metalloproteinases[@katz2004]. The active site coordinates a zinc ion essential for proteolysis, with the domain capable of processing a wide range of substrates including amyloid precursor protein (APP)[@chen2016], various cytokines, and growth factors such as heparin-bound epidermal growth factor (HB-EGF).
The metalloproteinase domain exhibits substrate specificity that is modulated by surrounding sequences and by interactions with other domains within the same protein. Research has shown that the catalytic efficiency varies depending on the substrate, with some studies suggesting ADAM15 may compensate for other ADAMs (such as ADAM10 and ADAM17) in processing certain substrates when those enzymes are limiting[@hure2019].
The disintegrin domain of ADAM15 contains a unique RGD (arginine-glycine-aspartic acid) sequence that mediates direct binding to integrins. This motif is rare among ADAM family members, making ADAM15 particularly important for integrin-mediated adhesion processes[@sauer2016]. The RGD sequence interacts with multiple integrin heterodimers, including αvβ3, α5β1, and αIIbβ3, enabling ADAM15 to function as both a receptor and a ligand for integrin binding.
Structural studies have revealed that the disintegrin domain adopts a characteristic fold that presents the RGD motif in an optimal conformation for integrin engagement. The binding affinity varies among different integrin receptors, with highest affinity for αvβ3 and α5β1 integrins, which are critically involved in angiogenesis and cell migration processes[@sauer2016].
Positioned between the disintegrin and transmembrane domains, the cysteine-rich domain contains multiple conserved cysteine residues that form disulfide bonds, stabilizing the overall structure. This domain also contributes to substrate recognition and may participate in interactions with extracellular matrix components. The cysteine-rich domain has been implicated in determining substrate specificity and in regulating the accessibility of the catalytic domain to potential substrates.
ADAM15 contains a single-pass transmembrane domain that anchors the protein to the plasma membrane. This membrane tethering is essential for ADAM15's function in processes occurring at the cell surface, including ectodomain shedding and cell adhesion. The transmembrane domain consists of a hydrophobic helix that spans the lipid bilayer, with the N-terminus extending into the extracellular space and the C-terminus projecting into the cytoplasm.
The intracellular cytoplasmic tail of ADAM15 contains several signaling motifs, including multiple SH3 (Src homology 3) binding sites. This region provides docking sites for signaling proteins containing SH3 domains, such as Src family kinases, Grb2, and other adaptor proteins. Through these interactions, ADAM15 participates in intracellular signaling cascades that regulate cell proliferation, differentiation, survival, and migration[@white2003].
The cytoplasmic tail also contains potential phosphorylation sites that may regulate ADAM15's function through post-translational modifications. Research suggests that phosphorylation events may modulate the catalytic activity, trafficking, or signaling functions of ADAM15 in response to various cellular stimuli.
ADAM15 plays a crucial role in mediating cell-cell and cell-matrix interactions through its integrin-binding capacity. The RGD motif in the disintegrin domain enables binding to multiple integrin receptors, facilitating leukocyte adhesion to the vascular endothelium during inflammatory responses[@hure2019]. This adhesion function is particularly important for immune cell trafficking and for maintaining tissue integrity.
In endothelial cells, ADAM15 promotes angiogenic processes by facilitating cell migration and proliferation. The protein is upregulated during active angiogenesis and contributes to the formation of new blood vessels through mechanisms involving both proteolytic processing of growth factors and direct integrin-mediated signaling[@martin2002].
The metalloproteinase activity of ADAM15 enables the shedding of membrane-bound precursors, releasing soluble bioactive molecules that regulate cellular functions. Key substrates include heparin-bound epidermal growth factor (HB-EGF), transforming growth factor-alpha (TGF-α), tumor necrosis factor-alpha (TNF-α), and various other growth factors and cytokines[@white2003].
This ectodomain shedding function is essential for normal development, tissue repair, and immune responses. The controlled release of these signaling molecules regulates processes including cell proliferation, differentiation, and inflammatory responses. Dysregulation of these proteolytic activities contributes to various pathological conditions.
ADAM15 participates in extracellular matrix (ECM) remodeling through both direct proteolytic degradation of matrix components and indirect mechanisms involving the release of matrix metalloproteinases (MMPs) and other ECM-degrading enzymes. This remodeling capacity is important for tissue morphogenesis, wound healing, and angiogenesis.
ADAM15 has emerged as a significant player in Alzheimer's disease pathogenesis through multiple mechanisms. Its expression is altered in AD brain tissue, and functional studies have implicated ADAM15 in vascular dysfunction, amyloid processing, neuroinflammation, and synaptic dysfunction.
One of the most significant roles of ADAM15 in AD relates to its function in the neurovascular unit and blood-brain barrier (BBB)[@choulerton2015]. ADAM15 is expressed in brain endothelial cells and pericytes, where it regulates vascular integrity and function. Studies have demonstrated that ADAM15 expression is altered in cerebral amyloid angiopathy (CAA), a condition characterized by amyloid deposition in cerebral blood vessels frequently observed in AD patients.
The protein modulates BBB integrity through effects on endothelial cell-cell junctions and on interactions between endothelial cells and pericytes[@nakamura2019]. Altered ADAM15 expression in AD contributes to BBB dysfunction, allowing increased permeability and infiltration of peripheral immune cells into the brain parenchyma. This vascular dysfunction exacerbates neuroinflammation and impairs clearance of amyloid-beta (Aβ) from the brain.
ADAM15 has been implicated in the proteolytic processing of amyloid precursor protein (APP), the precursor to amyloid-beta peptides that accumulate in AD brains[@chen2016]. While ADAM10 and ADAM17 are traditionally considered the primary α-secretases responsible for the non-amyloidogenic processing of APP, ADAM15 can also shed APP and may influence the amyloidogenic pathway indirectly.
Research indicates that ADAM15 expression levels correlate with APP processing efficiency in neurons. Knockdown of ADAM15 leads to increased amyloid-beta production in cellular models, suggesting a protective role against amyloidogenesis[@pruitt2018]. However, the exact mechanisms and the relative contribution of ADAM15 to APP processing in vivo remain areas of active investigation.
ADAM15 modulates neuroinflammatory responses through multiple mechanisms. The protein is expressed in microglia and astrocytes, where it regulates the production of pro-inflammatory cytokines and chemokines[@xu2021]. Studies have shown that ADAM15 expression is upregulated in response to inflammatory stimuli and that it can both promote and attenuate inflammation depending on the cellular context.
In AD models, ADAM15 has been shown to regulate the activation of the NF-κB pathway, a master regulator of inflammatory gene expression[@xu2021]. Aberrant NF-κB signaling contributes to chronic neuroinflammation, a hallmark of AD pathogenesis. ADAM15 may therefore represent a molecular link between amyloid pathology and the neuroinflammatory response.
Recent research has revealed that ADAM15 plays a role in modulating endoplasmic reticulum (ER) stress responses in neurons[@lucas2020]. ER stress is a key contributor to neuronal death in AD, and cells with impaired ER stress adaptation are more vulnerable to amyloid toxicity. ADAM15 expression appears to enhance neuronal resilience to ER stress through mechanisms involving the upregulation of adaptive stress response genes.
ADAM15 is expressed at synapses and participates in synaptic function and plasticity[@park2021]. In AD, synaptic dysfunction represents an early pathological change that correlates with cognitive decline. Studies have identified ADAM15 as a regulator of synaptic proteins and have shown that altered ADAM15 expression contributes to synaptic deficits in AD models.
The protein influences synaptic function through both proteolytic and non-proteolytic mechanisms. Proteolytic processing of synaptic adhesion molecules and receptors by ADAM15 modulates synaptic structure and function. Additionally, ADAM15-mediated integrin signaling contributes to synaptic plasticity processes underlying learning and memory.
ADAM15 is expressed in dopaminergic neurons of the substantia nigra, the neuronal population most vulnerable in Parkinson's disease[@seagar2019]. While the understanding of ADAM15's specific role in PD is less advanced than in AD, several lines of evidence suggest its involvement in PD pathogenesis.
Studies have detected ADAM15 expression in substantia nigra dopamine neurons, suggesting potential roles in neuronal survival and function[@seagar2019]. The protein may modulate the susceptibility of these neurons to various insults, including oxidative stress and neuroinflammation, both implicated in PD pathogenesis.
Similar to its role in AD, ADAM15 modulates neuroinflammatory responses in PD. Microglial activation and neuroinflammation contribute to dopaminergic neuron degeneration in PD, and ADAM15 may regulate these inflammatory processes. The protein's ability to modulate cytokine production and immune cell trafficking suggests potential involvement in the neuroinflammatory component of PD.
Several genetic studies have explored the relationship between ADAM15 polymorphisms and Parkinson's disease risk[@tang2020]. While findings have been inconsistent across populations, some studies suggest that specific ADAM15 variants may influence PD susceptibility. Further research is needed to clarify the genetic architecture underlying any ADAM15-PD relationship.
ADAM15 is significantly upregulated following ischemic brain injury and participates in both the acute injury response and subsequent recovery processes[@zhang2018].
Following cerebral ischemia, ADAM15 expression increases in the injured region and in surrounding tissue. This upregulation is thought to contribute to the inflammatory response and to blood-brain barrier disruption that characterizes acute stroke. The metalloproteinase activity of ADAM15 may participate in the degradation of vascular basement membranes and in the release of inflammatory mediators.
In the subacute and recovery phases of stroke, ADAM15 promotes post-ischemic angiogenesis, the process of forming new blood vessels to restore perfusion to ischemic tissue[@zhang2018]. This angiogenic function is mediated through ADAM15's integrin-binding activity and through the release of pro-angiogenic growth factors. The balance between beneficial angiogenesis and potentially detrimental inflammation determines the net effect of ADAM15 on stroke outcomes.
Given its roles in ischemic injury and recovery, ADAM15 has been explored as a potential therapeutic target for stroke treatment. Strategies targeting ADAM15 activity may modulate the inflammatory response, protect blood-brain barrier integrity, or promote regenerative angiogenesis depending on the timing and context of intervention.
Emerging evidence suggests potential roles for ADAM15 in amyotrophic lateral sclerosis, although this area of research is less developed. The protein's functions in neuroinflammation, vascular integrity, and neuronal survival may be relevant to ALS pathogenesis, which involves both motor neuron degeneration and vascular dysfunction.
ADAM15 expression is altered in multiple sclerosis lesions, suggesting potential involvement in demyelination and neuroinflammation processes. The protein's role in immune cell trafficking and cytokine processing may modulate autoimmune responses in the central nervous system.
Beyond its role in AD-associated vascular dysfunction, ADAM15 may contribute to vascular dementia more broadly. The protein participates in processes affecting cerebral blood flow, blood-brain barrier integrity, and small vessel disease, all of which are relevant to vascular cognitive impairment.
ADAM15 represents a potential therapeutic target for neurodegenerative diseases due to its multifaceted involvement in multiple pathogenic processes. Several strategies could be envisioned for targeting ADAM15 therapeutically.
Selective inhibitors of ADAM15 metalloproteinase activity could potentially reduce harmful proteolytic processing while preserving beneficial functions. However, the development of ADAM15-selective inhibitors is challenging due to the similarity among ADAM family active sites. Pan-ADAM inhibitors have shown promise in preclinical models but face challenges related to the broad physiological functions of these enzymes.
Monoclonal antibodies targeting ADAM15 could modulate its function through multiple mechanisms, including blocking integrin binding, inhibiting catalytic activity, or promoting receptor internalization. Antibody approaches offer potential advantages in terms of specificity but face challenges related to blood-brain barrier penetration for CNS-targeting applications.
Gene therapy approaches targeting ADAM15 expression could potentially modulate its levels in a controlled manner. Viral vector-mediated delivery of ADAM15 or its inhibitors could be used to manipulate ADAM15 function in specific cell types or brain regions.
Despite significant progress in understanding ADAM15 function, several key questions remain: